Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-12-05
2006-12-05
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C514S002600, C530S399000
Reexamination Certificate
active
07144577
ABSTRACT:
Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.
REFERENCES:
patent: 4588585 (1986-05-01), Mark et al.
patent: 4737462 (1988-04-01), Mark et al.
patent: 4904584 (1990-02-01), Shaw
patent: 4959314 (1990-09-01), Mark et al.
patent: 4965195 (1990-10-01), Namen et al.
patent: 5017691 (1991-05-01), Lee et al.
patent: RE33653 (1991-07-01), Mark et al.
patent: 5116943 (1992-05-01), Koths et al.
patent: 5120713 (1992-06-01), Mugica
patent: 5137872 (1992-08-01), Seely et al.
patent: 5534617 (1996-07-01), Cunningham et al.
patent: 5597709 (1997-01-01), Rosen et al.
patent: 5597797 (1997-01-01), Clark
patent: 5612470 (1997-03-01), Thorner et al.
patent: 5633352 (1997-05-01), Dalbøge et al.
patent: 5635604 (1997-06-01), Dalbøge et al.
patent: 5654010 (1997-08-01), Johnson et al.
patent: 5663146 (1997-09-01), Bowers et al.
patent: 5688666 (1997-11-01), Bass et al.
patent: 5696089 (1997-12-01), Felix et al.
patent: 5712380 (1998-01-01), Kendall et al.
patent: 5721250 (1998-02-01), Morriello et al.
patent: 5721251 (1998-02-01), Chen et al.
patent: 5723616 (1998-03-01), Houghton et al.
patent: 5726307 (1998-03-01), Schoen et al.
patent: 5726319 (1998-03-01), Lin et al.
patent: 5731317 (1998-03-01), Lu et al.
patent: 5767085 (1998-06-01), Johansen et al.
patent: 5767118 (1998-06-01), Nargund et al.
patent: 5767124 (1998-06-01), Draper et al.
patent: 5773441 (1998-06-01), Hipskind et al.
patent: 5776901 (1998-07-01), Bowers et al.
patent: 5777112 (1998-07-01), Nargund et al.
patent: 5792747 (1998-08-01), Schally et al.
patent: 5795957 (1998-08-01), Deghenghi
patent: 5798337 (1998-08-01), Somers et al.
patent: 5804578 (1998-09-01), Chakravarty et al.
patent: 5807985 (1998-09-01), Deghenghi
patent: 5830433 (1998-11-01), Dean et al.
patent: 5834598 (1998-11-01), Lowman et al.
patent: 5843453 (1998-12-01), Holder et al.
patent: 5846936 (1998-12-01), Felix et al.
patent: 5847066 (1998-12-01), Coy et al.
patent: 5849535 (1998-12-01), Cunningham et al.
patent: 5849700 (1998-12-01), Sørensen et al.
patent: 5849704 (1998-12-01), Sørensen et al.
patent: 5851992 (1998-12-01), Sørensen
patent: 5861379 (1999-01-01), Ibea et al.
patent: 5939386 (1999-08-01), Ibea et al.
patent: 6020311 (2000-02-01), Brazeau et al.
patent: 0075444 (1983-03-01), None
Wilson et al. (Metabolism, Clinical and Experimental. 1996; 45 (6): 738-746).
Carr et al., 5thConference on Retroviruses and Opportunistic Infections “A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PI's)”, Chicago, IL, p. 410 (Feb. 1-5, 1998).
Mulligan et al., 5thConference on Retroviruses and Opportunistic Infections “Evidence of unique metabolic effects of protease inhibitors”, Chicago, IL, p. 414 (Feb. 1-5, 1998).
Keruly et al., 5thConference on Retroviruses and Opportunistic Infections “Diabetes and hyperglycemia in patients receiving protease inhibitors”, Chicago, IL, p. 415 (Feb. 1-5, 1998).
Dong et al., 5thConference on Retroviruses and Opportunistic Infections “Diabetes and use of protease inhibitors”, Chicago, IL, p. 416 (Feb. 1-5, 1998).
Lo et al., “Buffalo hump” in men with HIV-1 infection,The Lancet,351:867-870 (Mar. 21, 1998).
Miller et al., “Visceral abdominal-fat accumulation associated with use of Indinavir”,The Lancet,351:871-875 (Mar. 21, 1998).
Viraben et al., “Indinavir-associated lipodystrophy”,AIDS,12:F37-F39 (1998).
Adelman et al., “In vitrodeletional mutagenesis for bacterial production of the 20,000-Dalton form of human pituitary growth hormone”,DNA,2:183-193 (1983).
Albertsson-Wikland et al., “Daily subcutaneous administration of human growth hormone in growth hormone deficient children”,Acta Poediatr Scand,75:89-97 (1986).
Becker et al., “Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormone”,Biotechnology and Applied Biochemistry,9:478-487 (1987).
Bewley et al., “The chemistry of human pituitary growth hormone”,Adv. Emzymol. Related Areas,42:73-166 (1975).
Denoto et al., “Human growth hormone DNA sequence and mRNA structure: possible alternative splicing”,Nucleic Acids Research,9:3718-3731 (1981).
Hendricks et al., “Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components”,Journal of Clinical Endocrinology and Metabolism,60:864-867 (1985).
Jørgensen et al., “Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man a double-blind cross-over study”,Acta Endocrinologica(Copenh), 116:381-386 (1987).
Jørgensen et al., “Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats”,Pharmacology&Toxicology,63:129-134 (1988).
Lewis et al., “An interchain disulfide dimmer of human growth hormone*”,The Journal of Biological Chemistry,252:3697-3702 (1977).
Lewis et al., “Enhancement of the hyperglycemic activity of human growth hormone by enzymic modification”,Endo,101:1587-1603 (1977).
Lewis et al., “Human Growth hormone: additional members of the complex*”,Endo,104:1256-1265 (1979).
Lewis et al., “Altered proteolytic cleavage of human growth hormone as a result of deamidation”,The Journal Of Biological Chemistry,256:11645-11650 (1981).
Ho et al., “Indinavir-associated facial lipodystrophy in HIV-infected patients”,AIDS Patient Care and STDs,13:11-16 (1999).
ABSTRACT No. PB0895—Muurahainen et al., Detection of occult wasting by BIA technology,International Conference AIDS,10(2)220 (Aug. 7-12 1994).
Viraben et al., “Fast Track indinavir-associated lipodystrophy”,AIDS,12::F37-F39 (1998).
Lewis et al., “The 20,000-Dalton variant of human growth hormone' location of the amino deletions”,Biochemical and Biophysical Research Communications,92:511-516 (1980).
Bjorntorp et al., “Abdominal obesity and the development of noninsulin-dependent diabetes mellitus”,Diabetes/Metabolism Reviews,4:615-622 (1998).
Jones et al., “Crystallization of authentic recombinant human growth hormone”,Biotechnology,5:499-500 (1987).
Martial et al., “Human growth hormone: complementary DNA cloning and expression in bacteria”,Science,602-607 (1979).
Bewley et al., “Sequence comparision of human pituitary growth hormone, human chorionic somatomammotropin, and ovine pituitary growth and lactogenic hormones”,Int. J. Peptide Protein Res.,4:281-287 (1972).
ABSTRACT 010—Cheng, “Lipodystrophy in HIV: a community perspective” (1999).
Cunningham et al., “Dimerization of human growth hormone by Zinc”,Science,253:544-548 (1991).
ABSTRACT 006—Engelson et al., “Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV Infection: interim analysis” (1999).
ABSTRACT 336*/32173—Kotler et al., “Alterations in body fat distribution in HIV-infected men and women”12 World AIDS Confer
Applied Research Systems ARS
Browdy and Neimark PLLC
Peng Bo
LandOfFree
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of HIV-associated dysmorphia/dysmetabolic syndrome..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of HIV-associated dysmorphia/dysmetabolic syndrome... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678690